Abstract
Background: Despite its grouping into canonical, organ-specific subtypes, cancer remains an individual disease. Within the malignant mass, each cell harbors patient-specific genetic, epigenetic and metabolic alterations that directly impact the response to therapy. Consequently, chemo-/immuno-therapeutic regimens should ideally be tailored to each individual patient to achieve optimal treatment responses. Initially focusing on colorectal cancer and liver metastases, 2cureX developed a functional assay system (IndiTreat® test) for testing the response to various chemotherapeutic agents, small molecule inhibitors and combinations thereof on primary micro-tumors (tumoroids), which are cultivated preserving their 3D structure. In our current study, we seek to further broaden the applicability of the IndiTreat® test to include immunotherapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
